ArticleVeterinary oncology (London, England)2025
Evaluating the impact of doxorubicin preconditioning on the efficacy of inhaled recombinant human IL-15 immunotherapy in dogs with pulmonary metastasis.
Article in Veterinary oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Background: Canine osteosarcoma (OSA) and melanoma are highly aggressive cancers with a high propensity for lung metastasis. A recent phase 1 trial demonstrated that inhaled recombinant human interleukin-15 (rhIL-15) immunotherapy is safe and may be effective against lung metastases in dogs with metastatic OSA or melanoma. Notably, baseline lymphopenia correlated with clinical benefit in that trial. Building on these findings, this study evaluates whether preconditioning with doxorubicin to induce transient lymphodepletion before inhaled rhIL-15 immunotherapy improves the overall response rate in dogs with metastatic melanoma or tumors of bone. Methods: Dogs with established pulmonary metastases from melanoma or bone tumors were treated with doxorubicin (30 mg/m Results: Ten dogs were enrolled, with eight reaching the Day 35 evaluable response assessment. One dog achieved a complete response lasting over 1 year, and two had stable disease, yielding an overall clinical benefit rate (CBR) of 30% and an overall response rate (ORR) of 10%. Doxorubicin preconditioning did not alter the toxicity of inhaled rhIL-15 therapy. While doxorubicin treatment decreased absolute lymphocyte counts (ALC), as expected, this reduction did not improve the CBR or ORR compared to the prior study evaluating inhaled rhIL-15 monotherapy. Transcriptomic analysis of peripheral blood mononuclear cells did not reveal a significant increase in natural killer or cytotoxic T-cell population frequencies following doxorubicin and inhaled rhIL-15 therapy. Conclusions: Preconditioning with standard doses of doxorubicin does not alter the clinical response or safety profile of inhaled rhIL-15 therapy in dogs with advanced pulmonary metastatic disease. Further research is needed to evaluate combinatorial treatment strategies that enhance the efficacy of inhaled rhIL-15 in dogs with advanced metastatic disease. Supplementary Information: The online version contains supplementary material available at 10.1186/s44356-025-00040-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.